Longevity's AI Bet, Policy Failures, and the Dark Side of Wellness

AI and biotech are pushing hard on longevity while policy makers struggle to keep up with access and potential harms, even in 'safe' wellness practices.

In today's read: 1. Longevity gets real, and AI's central to it · 2. GLP-1s: longevity drug, or equity nightmare? · 3. The Dark Side of 'Good for You' Trends · 4. Policy lags science on access and safety

1. Longevity gets real, and AI's central to it

Drug discovery and diagnostic tools are increasingly powered by AI to accelerate timelines and personalize treatments. From gene therapy to peptide selection, AI algorithms are crunching data to find novel pathways and deliver precision health at scale.

Watch for more funding to flow into AI-biotech firms. Companies not integrating AI into their research and development cycles will fall behind. Early adopters like Insilico Medicine are already proving their market value and attracting investment.

Evidence from today:

• LifespanningRx launches peptide discovery tool for clinical use — Longevity Technology — LifespanningRx released its Peptide Explorer, an online tool for clinicians to guide patients through selecting peptide therapy candidates. The 5-minute questionnaire helps users match health goals like metabolism or recovery with up to three peptides, simplifying the intake process for personalized treatment.
• Insilico Medicine AI drug discovery joins HKEX Tech 100 Index — Longevity Technology — Insilico Medicine, an AI-powered drug discovery company focused on longevity, was added to the HKEX Tech 100 Index. This move follows changes to the index's methodology to include emerging tech themes across the AI value chain, implemented after market close on September 11, 2026. It's a signal that financial markets see real muscle in AI's role in extending lifespan.
• Function Health lets you feed raw lab data to AI chatbots — Longevity.Technology — Function Health now allows its members to upload their personal lab results directly to AI platforms like ChatGPT, Claude, and Perplexity. This integration lets users get AI-generated health insights grounded in their own biological data, moving beyond generic web searches.
• AI models to map full patient journeys, not just single metrics — The Lancet — New AI models are moving beyond single clinical prediction scores, instead creating 'computable representations' of an entire patient's health journey. Published in The Lancet, this tokenization of fragmented medical records aims to make health data jointly computable over time. It means your whole medical history, from every doctor and hospital, could form one continuous, analyzable data stream.

2. GLP-1s: longevity drug, or equity nightmare?

GLP-1 agonists like semaglutide are showing anti-aging effects beyond weight loss and blood sugar control, impacting inflammation and lifespan markers. But their high cost and focus on pharmaceutical solutions threaten to divert resources from public health and worsen health equity.

The market will continue to expand GLP-1 applications, but regulators and public health advocates will push back on access and cost. Expect a continued fight over insurance coverage and a deeper look at the broader social implications of drug-led solutions for metabolic health.

Evidence from today:

• GLP-1s slow aging markers in mice, hinting at new uses — Nature News — New research in Nature shows that GLP-1 obesity drugs like semaglutide and liraglutide can slow several markers of aging in obese mice, including improved insulin sensitivity and reduced inflammation. The findings suggest these drugs might have broader benefits beyond weight loss and blood sugar control, extending to longevity pathways. This could reshape how we think about GLP-1s.
• Semaglutide slows aging, extends life in mice, new study finds — Deutsches Ärzteblatt — A new study in Nature found that regular semaglutide treatment extended the lifespan of older mice at a rate comparable to calorie restriction. Researchers observed significant anti-aging effects, suggesting GLP-1 agonists might do more than just manage blood sugar and weight. This is a big deal if it translates to human biology.
• GLP-1 boom could worsen health equity for obesity patients — Deutsches Ärzteblatt — Two public health experts, Luc Hagenaars from the University of Amsterdam and Laura Schmidt from UCSF, warn in a Science editorial that the widespread prescription of GLP-1 receptor agonists for obesity could unintentionally harm prevention efforts and healthcare equity. They argue that focusing on a pharmaceutical solution might pull resources and attention away from broader public health strategies. This could leave many people without access to effective, affordable obesity care.

3. The Dark Side of 'Good for You' Trends

Practices widely marketed as universally beneficial, like mindfulness, are revealing significant adverse effects for a notable percentage of users. This challenges the uncritical embrace of wellness trends, showing that even seemingly benign practices can induce anxiety, depression, or psychosis in vulnerable nervous systems.

The 'feel-good' narrative around many wellness practices is cracking. We’ll see more demand for evidence-based screening and personalized guidance in mindfulness and other popular interventions. Expect a reckoning for providers who overpromise universal benefits without acknowledging individual nervous system variability and potential risks.

Evidence from today:

• Mindfulness research reveals dark side effects — The Atlantic - Health — Dr. Willoughby Britton, a prominent psychologist and meditation teacher, uncovered significant adverse effects in her research on mindfulness practices. These range from anxiety and depression to psychosis, affecting a notable percentage of practitioners. Her findings challenge the prevailing narrative of meditation as universally beneficial.
• Health info online will get worse, thanks to AI — Croakey Health Media — Croakey Health Media warns that the integrity of online health information is set to degrade further due to unreliable AI summaries. This shift will make it harder for the public to discern accurate health advice, impacting everything from policy to personal well-being.

4. Policy lags science on access and safety

From gene therapies for sickle cell to new xenotransplantation methods, medical science is moving fast. But policy decisions are either failing to ensure sufficient post-market data collection for new treatments, or creating uneven access across populations. This leaves populations vulnerable and limits real-world evidence for long-term safety and efficacy.

Watch for increasing friction between rapid biotech innovation and slow-moving regulatory bodies. Public health policy will struggle to keep pace, leading to uneven access to cutting-edge treatments. This disparity will become a flashpoint in healthcare debates, especially for chronic and life-threatening conditions.

Evidence from today:

• Germany Skips Post-Market Data for Sickle Cell Gene Therapy — Deutsches Ärzteblatt — Germany's G-BA (Joint Federal Committee) decided against mandatory post-market data collection for Exagamglogen Autotemcel, a gene therapy for sickle cell disease. This means fewer real-world insights on long-term safety and efficacy will be gathered by the regulator. The decision impacts how closely this groundbreaking treatment's effects are monitored in Germany.
• Resolution Therapeutics partners to expand experimental liver therapy access — Longevity.Technology — Resolution Therapeutics teamed up with Blood Centers of America to make its RTX001 Regenerative Macrophage Therapy more accessible for US patients with end-stage liver disease. This partnership aims to get the experimental treatment into community settings, potentially changing how people manage late-stage liver problems.
• Pig kidney transplant patient gets human kidney after two months — Inside Precision Medicine — Tim Andrews, the first living human to receive a porcine kidney xenotransplant, survived dialysis-free for two months before successfully transitioning to a human kidney transplant. This case shows xenotransplantation's potential as a stop-gap, allowing more time for patients to receive compatible human organs. It's a huge step for organ shortage.
• Pig kidneys bridge waitlist for human transplants in US patients — Deutsches Ärzteblatt — Five patients in the US have received pig kidneys to tide them over until a human organ is available. Three of these patients avoided dialysis for over eight months, showing how xenotransplantation is becoming a real, albeit complex, option for organ failure.

Also moved today

• Lancet study argues women's health needs sex-specific precision medicine — The Lancet — A Lancet commentary argues for sex-specific precision medicine because healthcare often defaults to male biology, delaying diagnoses and increasing side effects for women.
• Danes eat more sugar, stay slimmer than Britons — The Conversation - Health & Medicine — Danes eat more sugar but stay slimmer than Britons, suggesting active transport and less processed food culture matter more than just sugar intake for metabolic health.
• Induced proximity drugs target specific protein interactions — Nature Medicine RSS — Induced proximity drugs, which force proteins to interact, are a new biotech approach gaining traction for targeting diseases traditional drugs can't reach, like neurodegeneration.
• Barilla buys Goodles, betting on 'better-for-you' mac and cheese — New Hope Network (Natural Products Expo) — Barilla acquired Goodles, a 'better-for-you' mac and cheese brand, signaling major food companies are moving into functional food to capture the convenience market.
• China OKs Leqembi self-injection for early Alzheimer's — Longevity Technology — China approved a self-injectable version of LEQEMBI for early Alzheimer's, making it easier for patients to administer the drug at home and increasing access to treatment.
• Startup VeriLeaf tracks supplement ingredient sources — Vitafoods Insights — Startup VeriLeaf is publishing Certificates of Analysis for supplement batches, pushing for transparency in a market without ingredient sourcing regulations.
• German Doctors Call for More STI Education on World Health Day — Deutsches Ärzteblatt — German doctors are calling for more STI education due to a widespread lack of public knowledge, highlighting a significant communication gap around sexual health.
• RNAi drug Kylo-11 cuts heart disease risk by lowering Lp(a) 25% — The Lancet — An RNAi drug, Kylo-11, reduced lipoprotein(a) (Lp(a)) by 20-25%, showing a new way to target a significant, often overlooked, risk factor for heart disease.
• E-cig vanillin harms embryo development in early stages — Deutsches Ärzteblatt — Research found vanillin, a common e-cigarette flavor, harms embryonic development, raising concerns about vaping products' impact on early fetal health.

New this week in wellness goods

• Function Health lets you feed raw lab data to AI chatbots — Function Health now allows its members to upload their personal lab results directly to AI platforms like ChatGPT, Claude, and Perplexity. This integration lets users get AI-generated health insights grounded in their own biological data, moving beyond generic web searches.
• LifespanningRx launches peptide discovery tool for clinical use — global — LifespanningRx released its Peptide Explorer, an online tool for clinicians to guide patients through selecting peptide therapy candidates. The 5-minute questionnaire helps users match health goals like metabolism or recovery with up to three peptides, simplifying the intake process for personalized treatment.

Signal map

UK & Ireland: 24 · Europe: 18 · North America: 16 · Global: 8 · Oceania: 2 · Nordics: 1

What I'd watch next

Pay attention to how regulatory bodies respond to GLP-1 data beyond weight loss. Look for new AI tools that combine lab data and medical history for a fuller patient picture, especially as consumers demand more personalized health insights.

Where this fits at Kokorology

These market signals highlight how much is still unknown about our personal biology. If you're looking to understand your own baseline, the Kokorology Nervous System Journal provides a framework to map your internal states, helping you track shifts in energy, mood, and sleep before the external world forces you to notice.